IMC-R117C

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameIMC-R117C
Drug Alias NameIMC-R-117-C
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulantsPiwi-like protein 1 inhibitors +[4] 
TargetsPiwi-like protein 1T cell surface glycoprotein CD3
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsItaly +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunocore Holdings PLC
China Registration ClassN/A

Develop Information

Active CompaniesImmunocore Holdings PLCImmunocore Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A